Vaccine candidate spurs elusive type of broadly neutralizing

An HIV vaccine candidate developed at the Duke Human Vaccine Institute triggered low levels of an elusive type of broadly neutralizing HIV antibodies among a small group of people enrolled in a 2019 clinical trial.

Related Keywords

, Lawrence Corey , Bartonf Haynes , Kristenw Cohen , Kevin Wiehe , Ruthj Parsons , Christopherb Fox , Susan Fetics , Amanda Eaton , Kara Anasti , Katayoun Mansouri , Gilad Ofek , Robertj Edwards , Tyler Evangelous , Jared Lindenberger , Maggie Barr , Benjaminm Janus , Katarzyna Janowska , Priyamvada Acharya , Wilton Williams , Bette Korber , Anagh Astavans , S Munir Alam , Jyue Chen , Mitchell Martin , Stephenr Walsh , Helene Kirshner , Kevin Saunders , Derekw Cain , Kshitij Wagh , Xiao Huang , Andrew Foulger , Elizabeth Van Itallie , M Juliana Mcelrath , Salam Sammour , Madison Berry , Lindseyr Baden , David Montefiori , Nathaniel Erdmann , Ipsita Mohanty , Duke Human Vaccine Institute , National Institutes Of Health , Duke University Medical Center , Melinda Gates Foundation , Duke Department Of Surgery , National Institute Of Allergy , University Medical , Robert Parks , Parth Patel , Aurelie Niyongabo , National Institute , Infectious Diseases , National Institutes ,